Sionna Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to redefining the treatment paradigm for cystic fibrosis (CF). Founded in 2019, the company is developing a pipeline of novel, differentiated small molecules designed to normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna's primary scientific focus is on directly stabilizing the first nucleotide-binding domain (NBD1) of the CFTR protein, which is the site of the F508del mutation—the most common genetic defect causing CF. In addition to its first-in-class NBD1 stabilizers, the company is advancing a complementary portfolio of CFTR modulators targeting the intracellular loop 4 (ICL4) and transmembrane domain 1 (TMD1) regions to enable highly effective combination therapies.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Develop first-in-class small molecules (SION-719 and SION-451) that directly target and stabilize the nucleotide-binding domain 1 (NBD1) of the CFTR protein to correct protein misfolding and restore function.
Expected impact: Establish clinical proof-of-concept for NBD1 stabilization as a disease-modifying mechanism in cystic fibrosis.
Combine NBD1 stabilizers with complementary CFTR modulators (such as TMD1-directed correctors or ICL4-directed correctors) to achieve full CFTR correction and deliver superior efficacy over the current standard of care.
Expected impact: Create a highly differentiated, fully proprietary multi-drug franchise to challenge the market dominance of Vertex Pharmaceuticals.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Sionna secured exclusive global rights to develop and commercialize multiple advanced clinical-stage CF compounds, including galicaftor (ABBV-2222/SION-2222), navocaftor (ABBV-3067/SION-3067), and ABBV-2851. This significantly expanded Sionna's pipeline of complementary modulators to pair with its proprietary NBD1 stabilizers.
Terms: AbbVie received an undisclosed upfront payment ($5.0 million cash upfront and $8.6 million non-cash expense recognized in 2024), an equity investment in Sionna, and is eligible for late-stage development and commercial milestones as well as royalties.